• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

    57.90 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Xenon Pharmaceuticals Inc. - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
    Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon... 
    Via Finterra
    Topics ETFs Intellectual Property
    News headline image
    Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner ↗
    Via Chartmill
    News headline image
    The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
    As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗
    Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo. 
    Via Stocktwits
    News headline image
    Xenon Pharmaceuticals Announces Proposed Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Top stock movements in today's session. ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Gapping stocks in Monday's session ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
    Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
    Via The Motley Fool
    News headline image
    Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
    Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
    Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
    Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
    Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
    This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
    Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
    This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
    As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their... 
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026
    The opening days of 2026 have ushered in a definitive regime shift in the global financial markets, as the long-awaited "Great Rotation" finally takes hold. After years of dominance by a handful of... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
    As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
    Via PredictStreet
    Topics Economy Intellectual Property
    News headline image
    Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
    Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.